Featured Research

from universities, journals, and other organizations

Researchers Successfully Test New Drug To Treat Acquired Haemophilia

Date:
July 21, 2006
Source:
Universitat Autonoma De Barcelona
Summary:
Researchers at the Universitat Autonoma de Barcelona Teaching Unit at Vall d'Hebron Hospital have developed a therapy to treat acquired haemophilia A. The therapy is based on the use of cyclosporin, which produces less side effects than the usual treatment based on using corticosteroids.

Researchers at the Universitat Autònoma de Barcelona Teaching Unit at Vall d'Hebron Hospital have developed a therapy to treat acquired haemophilia A. The therapy is based on the use of cyclosporin, which produces less side effects than the usual treatment based on using corticosteroids.

Acquired haemophilia A is an extremely rare disease that causes the sudden appearance of antibodies against coagulation factor VIII. This is therefore an autoimmune disease. This autoantibody, or inhibitor, impedes the activity of the factor VIII that collaborates in the normal coagulation cascade, meaning the patients have various haemorrhages in different parts of the body, especially on the skin, muscles and mucosae, which can be serious or life-threatening (the mortality rate without treatment is 30%).

The immunosuppressive treatments used to eradicate these autoantibodies are based mainly on using only corticosteroids or by combining corticosteroids with cytotoxic drugs (cyclophosphamide, vincristine, azathioprine). With cytotoxic drugs, however, there are many hematological or infectious side effects.

The UAB researchers have studied a more specific immunosuppressive therapy that has fewer side effects and is more tolerated by patients. They chose to use cyclosporin, which fits this pharmacological profile and had already been effective in a few cases of acquired haemophilia that did not improve when the traditional treatments were used.

From March 2001 to October 2003, five patients at Vall d'Hebron Hospital with acquired haemophilia were assessed. As soon as they were diagnosed they were treated with oral cyclosporin (3 to 5 mg/kg/day) and a daily intravenous infusion of corticosteroids (methylprednisolone 1g/day) over a period of three days. On day four, the treatment was changed to oral corticosteroids (prednisone 1mg/kg/day).

Cyclosporin and prednisone continued to be used until there was complete remission of the disease, ie, the complete disappearance of autoantibodies against coagulation factor VIII. Complete remission, with the disappearance of the inhibitor, was achieved for all patients after an average of four weeks from the start of the treatment.

Cyclosporin tolerance was good in all patients. Only one unusual neurological side effect was observed in one patient, but this quickly disappeared once the drug was no longer administered. In two years, no reappearance of the disease has been observed.

The researchers believe their study shows that it is probably beneficial to treat the disease first using cyclosporin associated with corticosteroids. This therapeutical option should be assessed in future studies.


Story Source:

The above story is based on materials provided by Universitat Autonoma De Barcelona. Note: Materials may be edited for content and length.


Cite This Page:

Universitat Autonoma De Barcelona. "Researchers Successfully Test New Drug To Treat Acquired Haemophilia." ScienceDaily. ScienceDaily, 21 July 2006. <www.sciencedaily.com/releases/2006/07/060721175524.htm>.
Universitat Autonoma De Barcelona. (2006, July 21). Researchers Successfully Test New Drug To Treat Acquired Haemophilia. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2006/07/060721175524.htm
Universitat Autonoma De Barcelona. "Researchers Successfully Test New Drug To Treat Acquired Haemophilia." ScienceDaily. www.sciencedaily.com/releases/2006/07/060721175524.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) — Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) — A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) — Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins